Literature DB >> 27439386

Persistent life-threatening hemorrhage after administration of idarucizumab.

Hussain M Alhashem1, Carmen Avendano1, Bryan D Hayes2, Michael E Winters3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27439386     DOI： 10.1016/j.ajem.2016.06.096

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN： 0735-6757            Impact factor:   2.469


× No keyword cloud information.
  5 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  ISMP Adverse Drug Reactions: Allergic Angina Caused by Fluconazole Rhabdomyolysis Caused by Risperidone High Incidence of Hyponatremia With High-Dose Trimethoprim-Sulfamethoxazole Lithium Carbonate-Induced Hypersalivation Persistent Hemorrhage After Idarucizumab Administration.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2017-09-11

3.  Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.

Authors:  Jonathan Balakumar; Ruben Santiago; Mark Supino
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-06

Review 4.  Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

Authors:  Stephanie A Kustos; Pius S Fasinu
Journal:  Medicines (Basel)       Date:  2019-10-15

5.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.